Protection against chemotherapy-induced alopecia: targeting ATP-binding cassette transporters in the hair follicle?

Trends Pharmacol Sci

The Dermatology Centre, Salford Royal NHS Foundation Trust and Institute of Inflammation and Repair, University of Manchester, Manchester, M13 9PT, UK. Electronic address:

Published: November 2013

Currently, efficacious treatments for chemotherapy-induced alopecia (hair loss) are lacking, and incidences of permanent hair loss following high-dose chemotherapy are on the increase. In this article, we describe mechanisms by which the pharmacological defense status of the hair follicle might be enhanced, thereby reducing the accumulation of cytotoxic cancer drugs and preventing or reducing hair loss and damage. We believe this could be achieved via the selective increase in ATP-binding cassette (ABC) transporter expression within the hair follicle epithelium, following application of topical agonists for regulatory nuclear receptors. Clinical application would require the development of hair follicle-targeted formulations, potentially utilizing nanoparticle technology. This novel approach has the potential to yield entirely new therapeutic options for the treatment and management of chemotherapy-induced alopecia, providing significant psychological and physical benefit to cancer patients.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tips.2013.09.001DOI Listing

Publication Analysis

Top Keywords

chemotherapy-induced alopecia
12
hair loss
12
atp-binding cassette
8
hair follicle
8
hair
7
protection chemotherapy-induced
4
alopecia targeting
4
targeting atp-binding
4
cassette transporters
4
transporters hair
4

Similar Publications

Response to Kearney et al, "Response to Kang et al, 'Efficacy of low-dose oral minoxidil in the management of anticancer therapy-induced alopecia in patients with breast cancer: A retrospective cohort study'".

J Am Acad Dermatol

December 2024

Department of Dermatology, Seoul National University College of Medicine, Seoul, Republic of Korea; Laboratory of Cutaneous Aging and Hair Research, Clinical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea; Institute of Human-Environment Interface Biology, Seoul National University, Seoul, Republic of Korea. Electronic address:

View Article and Find Full Text PDF

Chemotherapy-induced alopecia (CIA) represents one of the most common side effects of cancer treatment. Currently, scalp cooling systems are utilized to treat CIA, but their safety and effectiveness remain limited. The objective of this study was to investigate the effect of fucoidan on CIA and to elucidate the possible mechanism of fucoidan in treating CIA.

View Article and Find Full Text PDF

Purpose: Scalp cooling therapy (SCT) improves chemotherapy-induced alopecia (CIA), but there are few published data about its efficacy in an Asian-predominant population. We report our tertiary institution experience of SCT in patients with breast or gynaecological cancers undergoing chemotherapy.

Methods: The Paxman scalp cooling system was employed for eligible women with breast or gynaecological cancers receiving anthracycline or taxane-based chemotherapy.

View Article and Find Full Text PDF
Article Synopsis
  • Chemotherapy-induced alopecia can negatively affect patients' mental health, and this study explores using Phenylephrine, a topical vasoconstrictor, to potentially reduce hair loss during chemotherapy.
  • The research focused on improving the skin permeation and sustained release of Phenylephrine using different lipid vesicles (ethosomes, invasomes, transfersomes) incorporated into hydrogels.
  • Findings revealed that ethosomal and invasomal gels significantly improved drug delivery efficiency when compared to traditional gels, indicating their potential effectiveness in targeting local vasculature for sustained vasoconstriction.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!